期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1875, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2020.188482
关键词
ER-alpha signaling; DNA damage response; BRCA1
资金
- Indian Council of Medical Research, Government of India [53/20/2012-BMS]
- Science and Engineering Research Board, Department of Science and Technology, Government of India [EMR/2017/002222]
- Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India
- Department of Science and Technology (DST-INSPIRE), Government of India
- Indian Council for Medical Research, Government of India
- University Grants Commission, Government of India
- Science and Engineering Research Board, Department of Science and Technology, Government of India
- University of Kerala, Thiruvananthapuram
Individuals with BRCA1 mutations are more prone to developing cancers in hormone-responsive tissues, which do not respond well to hormone therapy and exhibit increased DNA damages. There is a cross regulatory signaling network between ER-alpha and BRCA1, and understanding this interaction is crucial for drug development and therapy for breast/ovarian cancers.
Carriers of BRCA1 mutations have a higher chance of developing cancers in hormone-responsive tissues like the breast, ovary and prostate, compared to other tissues. These tumors generally exhibit basal-like characters and do not express estrogen receptor (ER) or progesterone receptor (PR). Intriguingly, BRCA1 mutated breast cancers have a less favorable clinical outcome, as they will not respond to hormone therapy. BRCA1 has been reported to exhibit ligand dependent and independent transcriptional inhibition of ER-alpha; however, there exists a controversy on whether BRCA1 induces or inhibits ER-alpha expression. The mechanisms associated with resistance of BRCA1 mutated cancers to hormone therapy, as well as the tissue restriction exhibited by BRCA1 mutated tumors are still largely unknown. BRCA1 mutated tumors possess increased DNA damages and decreased genomic integrity, as BRCA1 plays a cardinal role in high fidelity DNA damage repair pathways, like homologous recombination (HR). The existence of cross regulatory signaling networks between ER-alpha and BRCA1 speculates a role of ER on BRCA1 dependent DDR pathways. Thus, the loss or haploinsufficiency of BRCA1 and the consequential deregulation of ER-alpha signaling may result in persistence of unrepaired DNA damages, eventually leading to tumorigenesis. Therefore, understanding of this cross-talk between ER-alpha and BRCA1, with regard to DDR, will provide critical insights to steer drug development and therapy for breast/ovarian cancers. This review discusses the mechanisms by which estrogen and ER signaling influence BRCA1 mediated DNA damage response and repair pathways in the mammalian system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据